I think the GSK share price could help you retire early

The GSK share price looks to have the potential to produce large total returns for long-term investors in the years ahead.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Of all the 100 different stocks in the FTSE 100, I think the GSK (LSE: GSK) share price has more potential to help you retire early than most. 

It all comes down to the company’s defensive nature. 

GSK share price growth 

Healthcare is one of the world’s most defensive markets. The treatments and products produced by GSK will always be required, and as the population grows, so will demand. 

But there’s more to GSK that its existing portfolio of drugs and medications. The company also spends billions of pounds every year researching new treatments. These products are designed to combat existing diseases and viruses, as well as new threats. The group is always trying to think of new ways to treat old problems and to address new issues. 

Management also considers acquisitions regularly. These efforts should help the company maintain its edge in the global pharmaceutical industry, not just in the short term, but in the long run as well.

This is the primary reason why the GSK share price could make an excellent buy-and-forget investment. Its products will always be in demand, and demand will only grow over the long run. That means to a certain extent the business runs itself. 

The company’s consumer pharmaceuticals division is another positive factor. Management is planning to spin off this business in the near term, which could create a windfall for shareholders. A special dividend or shares in the business may be distributed to existing GSK share price holders. 

Income returns 

It’s also good news for income seekers. GSK’s defensive business model means that the company has a relatively stable and predictable income stream from operations. This supports an attractive dividend yield on the GSK share price. 

Indeed, over the past few months, many FTSE 100 businesses have been forced to cut or eliminate their dividends to conserve cash in the coronavirus crisis. GSK is one of the few companies in the index that has not taken this course of action.

As a result, at the time of writing the stock supports a dividend yield of 4.9%, above the FTSE 100 average of around 4%. This looks set to continue as the dividend is well covered by earnings per share. The dividend cover stands at 1.5.

Retire early 

All of the above suggests that the GSK share price may be an excellent buy for any investor’s retirement portfolio. 

Over the long term, earnings per share should grow at least in line with inflation. That implies the company can achieve long-run earnings growth of 3% or more. Coupled with its 4.9% dividend yield, these numbers infer that the stock can produce total returns of 7.9% in the long term. 

This rate of return is more than enough to help you grow your financial nest egg. According to my calculations, an investment of £200 a month growing at a rate of 7.9% per annum could grow to be worth as much as £300,000 after 30 years. 

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Stack of one pound coins falling over
Investing Articles

Want to turn your ISA into a passive income machine? These 3 steps help

Christopher Ruane looks at a trio of factors he reckons could help an investor as they aim to earn passive…

Read more »

Investing For Beginners

2 FTSE shares that have been oversold in this stock market correction

Jon Smith reviews the recent market slump and points out a couple of FTSE shares he believes have been oversold…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

As the stock market moves down, I’m taking the Warren Buffett approach!

Rather than getting nervous as markets move around, our writer is looking to the career of Warren Buffett to see…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

Here’s how a stock market crash could be brilliant news for your retirement!

This writer isn't peering into a crystal ball trying to time the next stock market crash. Instead, he's making an…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Down 93%, should I load up on this penny stock while it’s under 1p?

The small-cap company behind this penny stock is eyeing up a substantial global market opportunity. So why did it crash…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Is Fundsmith Equity still worth holding in a Stocks and Shares ISA or SIPP in 2026?

The performance of the Fundsmith Equity fund has been shocking over the last two years. Is it still smart to…

Read more »

Young female hand showing five fingers.
Investing Articles

5 smart moves to make before the 2025/2026 ISA deadline

Taking advantage of the annual allowance isn’t the only smart move to make before the upcoming ISA deadline, says Edward…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Here’s the dividend forecast for Lloyds shares through to 2028

Can dividend forecasts tell investors much about the outlook for banking shares? Stephen Wright sets out what investors really need…

Read more »